NRx Pharmaceuticals
Radnor, Florida, United States · Biopharma, Biotechnology, Health Care
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About NRx Pharmaceuticals, Inc. Clinical-stage biopharmaceutical company developing thera
Key facts
- Headquarters
- Radnor, Florida, United States
- Employees
- 21
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (NRXP)
- Website
- nrxpharma.com
- Company page
Recent activity at NRx Pharmaceuticals
- : SEC 8-K (8.01): On September 15, 2026, NRx Pharmaceuticals, Inc. announced via a press release that it received communication from the FDA indicating that its amendment to the Abbreviated New Drug Application (ANDA), which was initially classified as a Major Amendment, has now been reclassified as a Minor Amendment. This change has revised the GDUFA goal date to November 10, 2026, noting that the reclassification will not necessitate a substantial use of FDA resources. This adjustment could streamline the approval process for NRx Pharmaceuticals' generic drug application, potentially facilitating market entry and affecting the company's strategic position in the pharmaceutical sector.
- : NRx Pharmaceuticals Appoints Glenn Tyson as Chief Commercial Officer
- : SEC 8-K (8.01): On February 17, 2026, NRx Pharmaceuticals, Inc. issued a press release discussing its path to a new drug application for NRX-100 (ketamine), informed by real-world data and proposing a broader indication. This release follows a Type C meeting with the FDA, indicating significant progress in their drug development strategy. The information in the press release, attached as Exhibit 99.1, is crucial for stakeholders as it outlines potential advancements in treatment options.
- : NRx Pharmaceuticals and neurocare Group AG establish partnership to create a nationwide network for neuroplastic therapy for depression and PTSD.
- : NRx Pharmaceuticals and HOPE Therapeutics Form Strategic Investor Relations Partnership with astr partners.
- : NRx Pharmaceuticals
- : NRx Pharmaceuticals Appoints Michael Abrams as Chief Financial Officer
- : Nrx Pharmaceuticals Closes $11 Million Unsecured Debt Financing
NRx Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2025 | Seed | $3.5M |
| Nov 2022 | Debt Financing | $11.0M |
Leadership
- Matt Duffy, Chief Business Officer, Co-CEO
- Jonathan Javitt, Chief Executive Officer
- Glenn Tyson, Chief Commercial Officer
- Drew Evans, Director
- Jonathan Javitt, Chief Executive Officer
Verified email and direct lines for NRx Pharmaceuticals’s decision-makers are on Fundz. See plans
NRx Pharmaceuticals in the news
- NRx Pharmaceuticals to Participate in Upcoming Investor Conferences - Investing News Network (Sep 08, 2026)
- Three New York investor events are planned for NRx Pharmaceuticals in September. - Stock Titan (Sep 08, 2026)
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression - PR Newswire (Aug 11, 2025)
- NRx Pharmaceuticals to Release Q3 2025 Financial Results and Host Conference Call on November 17, 2025 - Quiver Quantitative (Nov 12, 2025)
- New Expanded Access Policy for NRX-100 for Suicidal Ideation - Psychiatric Times (Aug 27, 2025)
- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter and Year to Date 2024 Financial Results on August 14, 2024 - BioSpace (Aug 13, 2024)
- NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections - PR Newswire (Dec 18, 2023)
- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025 - Finansavisen (Apr 21, 2025)
Companies similar to NRx Pharmaceuticals
- Citius Oncology · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Delta-Fly Pharma · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Vanda Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Monopar Therapeutics · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
About NRx Pharmaceuticals: questions and answers
What does NRx Pharmaceuticals do?
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About NRx Pharmaceuticals, Inc. Clinical-stage biopharmaceutical company developing thera
Where is NRx Pharmaceuticals headquartered?
NRx Pharmaceuticals is headquartered in Radnor, Florida, United States.
How many employees does NRx Pharmaceuticals have?
NRx Pharmaceuticals has about 21 employees.
Has NRx Pharmaceuticals raised funding?
Yes. Fundz has recorded 2 funding events for NRx Pharmaceuticals. The most recent, Seed of $3.5M, was in Mar 2025.
Who leads NRx Pharmaceuticals?
Matt Duffy is a Chief Business Officer, Co-CEO at NRx Pharmaceuticals.
What is the latest news on NRx Pharmaceuticals?
On Sep 15, 2026, SEC 8-K (8.01): On September 15, 2026, NRx Pharmaceuticals, Inc. announced via a press release that it received communication from the FDA indicating that its amendment to the Abbreviated New Drug Application (ANDA), which was initially classified as a Major Amendment, has now been reclassified as a
Is NRx Pharmaceuticals a public company?
Yes. NRx Pharmaceuticals is publicly traded under the ticker NRXP.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy